Ellington Management Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Ellington Management Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-2,900	Closed	-$690K	–	434
2020 Q1	$690K	Buy	+2,900	New	+$665K	0.16%	176
2018 Q4	–	Sell	-1,100	Closed	-$212K	–	611
2018 Q3	$212K	Sell	1,100 -1,400	-56%	-$249K	0.06%	434
2018 Q2	$425K	Sell	2,500 -300	-11%	-$46.5K	0.03%	201
2018 Q1	$456K	Buy	+2,800	New	+$457K	0.03%	436
2017 Q4	–	Sell	-1,900	Closed	-$289K	–	830
2017 Q3	$289K	Sell	1,900 -4,000	-68%	-$602K	0.05%	403
2017 Q2	$760K	Buy	5,900 +1,100	+23%	+$132K	0.11%	140
2017 Q1	$525K	Buy	+4,800	New	+$423K	0.02%	293
2015 Q3	–	Sell	-2,600	Closed	-$321K	–	916
2015 Q2	$321K	Buy	+2,600	New	+$328K	0.08%	392
2014 Q2	–	Sell	-8,500	Closed	-$601K	–	672
2014 Q1	$601K	Buy	+8,500	New	+$673K	0.18%	169

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Ellington Management Group's VRTX Position: Q2 2020 in Review

Ellington Management Group sold out of Vertex Pharmaceuticals (VRTX) in Q2 2020, closing a stake of 2,900 shares — an estimated $690K sold.

Ellington Management Group first reported a position in VRTX in Q1 2014 and held it in 9 quarters. The position peaked at $760K in Q2 2017. 963 funds tracked by Wall St. Rank hold VRTX as of Q2 2020.

Ellington Management Group reported no remaining Vertex Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Ellington Management Group sold 2,900 Vertex Pharmaceuticals shares in Q2 2020, an estimated $690K.
Ellington Management Group first reported a position in Vertex Pharmaceuticals in Q1 2014 and held it in 9 quarters.
Ellington Management Group's Vertex Pharmaceuticals position peaked at $760K in Q2 2017.
963 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2020.

Based on Ellington Management Group's 13F filing for Q2 2020, filed 17 Aug 2020.